Caroline Truntzer
Caroline Truntzer is an expert in Oncology at Centre Georges François Leclerc (France). Caroline Truntzer has authored 143 publications, the most recent in 2026. SLR score: 429 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Immunology - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2007 - 2026
Number : 143
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Subclinical cholestasis is a hallmark of gut dysbiosis causing resistance to cancer immunotherapy. PMID 42526445 — dysbiosis, cells, cholestasis, deoxycholic acid, neoplasms, immunotherapy, gastrointestinal microbiome, plasma | Cancer Cell Top journal | 2026 | 1 |
| An expression signature of 19 human endogenous retroviruses identifies immunogenic luminal breast cancers likely to respond to immunotherapy. PMID 42382385 — breast neoplasms, retroviridae, neoplasms, immunotherapy, signs and symptoms, breast, viruses, prognosis, endogenous retroviruses, immunology | Front Oncol | 2026 | 0 |
| IL-10 secretion by CD8 T cells orchestrates early NK cell recruitment and antitumor immunity after anti-VEGFR-2/PD-1 therapy. PMID 42331382 — cells, killer cells, natural, macrophages, neoplasms, immunotherapy, immunity, vascular endothelial growth factor receptor-2, therapeutics, colorectal neoplasms, interleukin-10, angiogenesis | J Immunother Cancer | 2026 | 1 |
| The mannosyltransferase DPM1 regulates the activity of ER-stress sensor IRE1 in colorectal cancer. PMID 42230629 — cells, biological science disciplines, stress, physiological, neoplasms, mannosyltransferases, therapeutics, colorectal neoplasms | Nat Commun | 2026 | 0 |
| Deep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohorts. PMID 42100890 — neoplasms, colon, biomarkers, deep learning, therapeutics, learning, prognosis, colonic neoplasms | Oncoimmunology | 2026 | 0 |
LeadR Networks
Main global connection map